Lamictal

Lamotrigine, the active ingredient in Lamictal, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed for the management of epilepsy, for stabilization of mood in bipolar disorder, and as an adjunct treatment for major depressive disorder in adults.

GNH USA supplies Lamictal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border procurement. Customers benefit from reliable supply chains, transparent pricing, and dedicated technical assistance.

Lamotrigine is used in several neurological and psychiatric conditions, targeting seizure activity and mood regulation.

- Epilepsy: Reduces frequency and severity of partial and generalized seizures. - Bipolar disorder: Helps prevent depressive and manic episodes, stabilizing mood. - Major depressive disorder (adjunct): Enhances response when added to standard antidepressant therapy.

Lamotrigine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dizziness: sensation of light‑headedness or imbalance. - Nausea: upset stomach, sometimes with vomiting. - Rash: mild skin irritation or maculopapular eruption.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Aseptic meningitis: inflammation of the meninges without infection. - Blood dyscrasias: rare cases of agranulocytosis or aplastic anemia.

When prescribing lamotrigine, clinicians should consider several safety precautions to minimize risk.

- Initiate therapy at low dose: gradual titration reduces risk of skin reactions. - Monitor for rash: discontinue immediately if a widespread or severe rash develops. - Assess hepatic function: adjust use in patients with significant liver impairment. - Review concomitant valproate: dose may need reduction due to interaction. - Pregnancy counseling: potential risks require discussion with the patient. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Lamotrigine interacts with several medicines that can alter its plasma concentration or increase adverse effect risk.

Major Interactions (Avoid): - Valproic acid: markedly increases lamotrigine levels; co‑administration requires dose reduction. - Carbamazepine: induces metabolism, lowering lamotrigine concentrations and reducing efficacy. - Phenobarbital: accelerates clearance, potentially leading to sub‑therapeutic levels.

Moderate Interactions (Monitor Closely): - Oral contraceptives: estrogen‑containing pills may reduce lamotrigine levels, requiring monitoring. - Phenytoin: may modestly decrease lamotrigine concentrations. - Serotonergic agents: combined use may increase risk of serotonin syndrome, though rare.